MedTrace Logo

Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

NCT00589927 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2010-03-18

No results posted yet for this study

Summary

To evaluate whether the cilostazol reduce neointimal hyperplasia after ZES (Zotarolimus-eluting stents) implantation, the investigators performed double-blind,randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol) and dual antiplatelet therapy (aspirin plus clopidogrel) for 8 months in patients with long coronary lesion treated with ZES.

Conditions

Interventions

DRUG

cilostazol

cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months

DRUG

placebo

placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months

Sponsors & Collaborators

  • Otsuka Korea

    collaborator UNKNOWN

  • CardioVascular Research Foundation, Korea

    lead OTHER

Principal Investigators

  • Seung-Wook Park, MD,PhD · Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00589927 on ClinicalTrials.gov